Tesamorelin tracker
for iPhone.
Tesamorelin is the prescription end of the GHRH family — FDA-approved as Egrifta for HIV-related visceral fat reduction, then borrowed into longevity and body-recomposition self-protocols. The cadence is daily, the math is unfussy, and the discipline is "actually do it every night for twelve weeks." Peptide Protocol sits in the middle of that loop and keeps the streak honest.
Download Peptide Protocol — FreeTesamorelin at a glance
Verified against the current FDA prescribing information / regulatory record. For mechanism, primary-literature sourcing, and a fuller pharmacology view, follow the cross-link to our sister site.
| Class | GHRH analog |
|---|---|
| Brand names / aliases | Egrifta, Egrifta SV |
| Regulatory status | FDA-approved (Egrifta SV) |
| Evidence level | Official label |
| Plasma half-life | Short — minutes range per Egrifta SV label. |
| Approved presentation | Egrifta SV: 2 mg vial powder, reconstituted with the supplied diluent per label. Older Egrifta product differs. |
| Dose initiation | Egrifta SV: 1.4 mg once daily SC. Approved indication: HIV-associated lipodystrophy (excess abdominal fat). |
| Escalation | No escalation; fixed daily dose per label. |
| Side-effect notes | Raises IGF-1; not appropriate as a generic anti-aging GH substitute. Hyperglycemia, injection-site reactions, fluid retention per label. |
| Key caveat | Egrifta SV (1.4 mg/day) and the older Egrifta product use different presets — do not mix the two. Off-label use beyond the HIV-associated lipodystrophy indication is a clinical decision, not an app-driven one. |
For full Tesamorelin background and primary-literature sourcing, see the Tesamorelin guide on peptide-calc.app.
Built around Tesamorelin protocols
Three things daily GHRH protocols actually need.
Daily streak that survives travel
12-week protocols don't survive forgotten doses. The Today screen shows tonight's dose and the streak count; iCloud-free local storage means the data is on the device that's with you, not in a cloud you have to log into.
Vial-friendly math
The Egrifta SV preset (2 mg vial, supplied diluent, 1.4 mg label dose once daily) is built in. The calculator displays the unit count cleanly and flags when you're near the syringe's max volume. Override the default for older Egrifta, compounded vials, or off-label concentrations.
Body-comp insights
Daily check-ins capture weight and waist measurement (the metric the FDA trial used). The Insights tab charts trend over the cycle so the visceral-fat hypothesis you started with can be checked against real numbers.
What it looks like
Tesamorelin tracking — common questions
Does Peptide Protocol have a Tesamorelin preset?
Yes — Tesamorelin is a calculator preset, with a sensible default for the FDA-approved Egrifta SV product (2 mg vial reconstituted with the supplied diluent, label dose 1.4 mg once daily SC). If you're running a different presentation (older Egrifta, compounded vial, or a different concentration), you can override the defaults with your own vial mass and BAC water volume.
Tesamorelin or CJC-1295 — which one fits in the app?
Both. They're both GHRH analogs but Tesamorelin is the FDA-approved one (for HIV-related lipodystrophy under brand name Egrifta), short-acting like Mod GRF, and used daily. CJC-1295 with DAC is long-acting, weekly. The protocol-builder handles either: pick the compound and the cadence follows.
Can I stack Tesamorelin with Ipamorelin?
Yes. Tesamorelin (GHRH) plus Ipamorelin (GHRP) is a common alternative to the CJC / Ipa blend. Run them as parallel protocols — one daily, one nightly with whatever timing you've chosen — and the Today screen surfaces both. Calculator math for each runs independently, so no cross-contamination.
Related peptide trackers
Track your Tesamorelin on your iPhone.
Free on the App Store. Builds your first protocol in under five minutes. No account required.
Download on the App StoreData sources
This page is fact-checked against the current regulatory record. Last verified 2026-05-09.
Not medical advice. Tesamorelin (Egrifta) is a prescription medication FDA-approved for HIV-related lipodystrophy. Off-label use is a clinical decision, not an app-driven one. The information on this page is informational and based on the Egrifta prescribing information. Always consult a licensed healthcare professional before starting, modifying, or stopping any compound. See the full Tesamorelin reference for primary sources.